ReviewProbiotics and antimicrobial proteins2026
The Biofilm Plight in Healthcare: Orchestration and Control by Lactiplantibacillus plantarum.
Review in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Postbiotics and phage synergy in precision oral microbiome engineering: systems biology strategies targetingFrontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The clinical consequences of biofilm-related infections are on the rise. Biofilm-related infections represent a mounting burden on healthcare worldwide, posing a significant challenge to patient care and health infrastructure. Another notorious function that needs to be underlined is the association of biofilms with medical devices. Considering the fact that bacteria under biofilm make them virulent and resistant to antibiotics, targeting the biofilms is a crucial area of investigation. Therefore, alternative approaches that extend beyond conventional antibiotic therapies are necessary to overcome biofilm-related infections. In this regard, Lactiplantibacillus plantarum, a probiotic bacterium, has lately shown promising outcomes as an antibiofilm agent. Largely renowned for its antimicrobial metabolite production, L. plantarum could be a potential alternative to improve biofilm-related treatment and its cost associated with biofilm infections. Therefore, the present review aims to provide a comprehensive understanding and implications of L. plantarum as an antibiofilm agent regardless of its biological form against pathogens in healthcare. Additionally, the potential of L. plantarum as a biofilm producer and its engineered applications in clinical applications and therapeutic use will also be discussed in this review.
Indexed as
Identifiers
41484511What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.